Acedia

Acedia Therapeutics is a biotechnology company focused on the discovery and development of small molecule therapeutics for previously undruggable protein targets. The company utilizes a proprietary platform that integrates high-throughput computational drug design with experimental chemical biology to identify novel binding pockets and develop potent degraders or inhibitors. Acedia's primary therapeutic focus is oncology, where it aims to address high-value targets such as transcription factors that have historically eluded traditional drug discovery efforts. By leveraging advanced modeling and screening techniques, the company seeks to expand the reach of small molecule drugs to treat cancers with high unmet medical needs. Headquartered in San Francisco, Acedia is supported by prominent venture capital investors and was a participant in the Illumina Accelerator program.